Lincoln National Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lincoln National Corp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,430	Closed	-$286K	–	863
2021 Q2	$286K	Sell	3,430 -29	-0.8%	-$2.3K	0.01%	685
2021 Q1	$261K	Buy	3,459 +120	+4%	+$9.8K	0.01%	670
2020 Q4	$293K	Hold	3,339	–	–	0.01%	581
2020 Q3	$254K	Sell	3,339 -400	-11%	-$40.5K	0.01%	549
2020 Q2	$461K	Sell	3,739 -540	-13%	-$53.7K	0.01%	390
2020 Q1	$362K	Hold	4,279	–	–	0.01%	399
2019 Q4	$362K	Buy	+4,279	New	+$323K	0.01%	458
2018 Q1	–	Sell	-3,910	Closed	-$349K	–	504
2017 Q4	$349K	Buy	+3,910	New	+$340K	0.01%	446

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Lincoln National Corp's BMRN Position: Q3 2021 in Review

Lincoln National Corp sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 3,430 shares — an estimated $286K sold.

Lincoln National Corp first reported a position in BMRN in Q4 2017 and held it in 8 quarters. The position peaked at $461K in Q2 2020. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Lincoln National Corp reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Lincoln National Corp sold 3,430 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $286K.
Lincoln National Corp first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Lincoln National Corp's BioMarin Pharmaceuticals position peaked at $461K in Q2 2020.
511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Lincoln National Corp's 13F filing for Q3 2021, filed 5 Nov 2021.